

Supplementary Materials:

Supplementary Figures:




Figure S1. Gene expression in MSCs normal mouse bone marrow (A) Cell clusters gated for the following single gene analyses are marked by red frame. *Nrp2* and *Ncam1* expression shown in cell clusters including osteogenic lineage. *Lepr* is highly expressed in Adipo-CAR cells and shows a similar expression pattern to *Nrp1*. (B) Osteogenic markers (*Bglap*, suggesting an osteogenic potential in all of these cell clusters. (C) Velocity plots showing either *Nrp2* (left) or *Ncam1* (right) expression in the mesenchymal trajectories. *Ibsp*, *Runx2*, *Apl*, *Sp7*, *Tnfrsf11b* are expressed in Adipo-/Osteo-CAR, *Ng2*-MSC and osteoblasts, suggesting an osteogenic potential in all of these cell clusters. Grey dots label cells that do not express the gene of interest. (C) Velocity plots showing either *Nrp2* (left) of *Ncam1* (right) expression in the mesenchymal trajectories. Arrows indicate the trajectory of differentiation.





Figure S2. Protein expression of MC-3T3 E1 cells during osteogenic differentiation in the presence or absence of *Nrp2*. Western blot (see methods) showing knockout of *Nrp2* (IB: *Nrp2*) in MC3T3 *Nrp2*-KO (right panel) versus MC3T3 wt (left panel) as compared to persistent expression of *Ncam1* protein (IB: *Ncam1*) in both cell lines. Cell lines were subjected to either osteogenic differentiation conditions (osteogenesis) or control conditions (control) and analyzed at day 1 (d1), day 3 (d3), day7 (d7), day 14 (d14) and day 21 (d21).

Supplemental Methods and Data:



CRISPR/Cas9-mediated generation of *Nrp2*-deficient MC3T3-E1 cells. (A) Schematic representation of the *Nrp2* gene locus and targeting strategy for CRISPR/Cas9-mediated generation of *Nrp2*-deficient MC3T3-E1 cells. Targeting sites of guide RNAs are depicted by red arrows. Genotyping primer binding sites are depicted by black arrows. *Nrp2*-deficient MC3T3-E1 cells were generated by nucleofection of ribonucleoprotein (RNP) complexes using a 4D nucleofector system (Lonza, Cologne, Germany). For ribonucleoprotein (RNP) formation, crRNA (see (B) for sequence details) and tracrRNA (IDT, Leuven, Belgium) were combined in IDTE buffer (IDT) to a final concentration of 100 μ M and annealed (95°C, 5 min; cool down to room temperature with -0,2°C/sec.). For RNP assembly, 21 μ M high-fidelity Cas9 protein (IDT), and 12 μ M of each cr/tracrRNA were combined in PBS and incubated for 15 min at room temperature. Nucleofection was performed using the Amaxa SE Cell Line 4D-Nucleofector X Kit (catalog-no. V4XC-1032, Lonza) according to the manufacturers instructions. Briefly, 1.5x10⁵ cells were pelleted by centrifugation (800 rpm, 7 min) and resuspended in 20 μ l Nucleofector SE solution. Cells were supplemented with 5 μ l of RNP and 1 μ l 100 μ M Electroporation Enhancer (IDT). Nucleofection was performed using program CM-137. Subsequently, cells were resuspended in 70 μ l pre-warmed culture medium, seeded (in one well of a 12 well-plate supplemented with 1 ml culture medium) and incubated for 48 h in a tissue culture incubator (37°C, 6% CO₂). To generate monoclonal *Nrp2*-deficient cell lines, single cells of the bulk population were seeded in 96-well plates by limiting dilution cloning. Established monoclonal cell lines were genotyped by PCR. PCR reactions were assembled according to the manufacturers protocol of the DreamTaq Green DNA Polymerase (EP0712, Thermo Fisher, Paisley, UK) using gene-specific primers listed in (C).

Original immunoblots (IB) related to Fig. S2 of osteodifferentiation in the presence (Nrp2 WT) or absence (Nrp2-KO) of neuropilin 2. Antibodies directed against Ncam1, Nrp2 or β actin were used.

